New anticoagulants, reversal agents, and clinical considerations for perioperative practice

Hart, Brendon M.; Ferrell, Stephane M.; Motejunas, Mark W.; Bonneval, Lauren A.; Cornett, Elyse M.; Urman, Richard D.; Kaye, Alan D.

doi:10.1016/j.bpa.2018.06.008

Cited by 8 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The newer class of oral direct factor Xa inhibitors may be associated with greater compliance after discharge compared to parenteral treatments, and also with a lower risk for VTE, but these drugs appear to carry a higher risk of bleeding complications [5]. Still, these new drugs (as well as agents that can reverse them in patients who are experiencing a bleeding complication) are being introduced to the market at a rapid rate [4]. Therefore, a collaborative multidisciplinary approach with specialists in hematology would be important going forward as we seek to identify the best thromboprophylactic approach for cancer patients with spine metastases.…”

Section: Where Do We Need To Go?mentioning

confidence: 99%

CORR Insights®: High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study

Ghert

2019

Clin Orthop Relat Res

View full text Add to dashboard Cite

The author certifies that neither she, nor any members of her immediate family, have any commercial associations (such as consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article. The opinions expressed are those of the writer, and do not reflect the opinion or policy of CORR ® or The Association of Bone and Joint

show abstract

Section: Where Do We Need To Go?mentioning

confidence: 99%